June 8, 2021 -- Pharmaceutical artificial intelligence (AI) technology developer Auransa and quantum computing drug design firm Polaris Quantum Biotech have formed a research collaboration aimed at finding therapeutics for neglected diseases that disproportionately affect women.
The initiative will target diseases such as endometriosis, polycystic ovary syndrome, triple-negative breast cancer, or ovarian cancer, according to the companies. Auransa will utilize its SMarTR Engine predictive computational software and make use of a pipeline of novel compounds for various diseases.
For its part, Polaris will provide its Tachyon drug discovery platform, which scans billions of molecules from a large chemical space to find novel molecular drugs, the companies said.
Copyright © 2021 scienceboard.net